KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Operating Leases (2019 - 2025)

Historic Operating Leases for Sarepta Therapeutics (SRPT) over the last 7 years, with Q3 2025 value amounting to $215.0 million.

  • Sarepta Therapeutics' Operating Leases rose 2648.86% to $215.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.0 million, marking a year-over-year increase of 2648.86%. This contributed to the annual value of $192.5 million for FY2024, which is 3653.96% up from last year.
  • As of Q3 2025, Sarepta Therapeutics' Operating Leases stood at $215.0 million, which was up 2648.86% from $214.4 million recorded in Q2 2025.
  • Over the past 5 years, Sarepta Therapeutics' Operating Leases peaked at $215.0 million during Q3 2025, and registered a low of $35.2 million during Q3 2022.
  • Its 5-year average for Operating Leases is $112.7 million, with a median of $129.2 million in 2023.
  • Its Operating Leases has fluctuated over the past 5 years, first plummeted by 4834.7% in 2021, then soared by 28250.31% in 2023.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Operating Leases stood at $41.5 million in 2021, then soared by 38.7% to $57.6 million in 2022, then skyrocketed by 144.82% to $141.0 million in 2023, then soared by 36.54% to $192.5 million in 2024, then grew by 11.73% to $215.0 million in 2025.
  • Its Operating Leases stands at $215.0 million for Q3 2025, versus $214.4 million for Q2 2025 and $205.5 million for Q1 2025.